{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069747","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.967056+00:00","generated_at":"2026-06-07T14:15:32.947000+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Crinetics amends bylaws to adopt universal proxy rules and enhance stockholder proposal disclosures","bullets":["Amended bylaws to comply with SEC universal proxy rules, requiring compliance with Rule 14a-19 for soliciting proxies.","Enhanced procedural and disclosure requirements for stockholder nominations and proposals, including additional background info.","Requires stockholder solicitors to use a proxy card color other than white.","Amendments effective December 6, 2023; include technical and clarifying changes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069747","json":"https://secwatch.observer/filing/0000950170-23-069747.json","markdown":"https://secwatch.observer/filing/0000950170-23-069747.md","text":"https://secwatch.observer/filing/0000950170-23-069747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023069747/0000950170-23-069747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023069747/crnx-20231206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:15:32.947000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d1168c85710802298768ced425650c7c5c968ef","claim":"Crinetics Pharmaceuticals, Inc.: Amended bylaws to address universal proxy rules, enhance stockholder nomination and proposal disclosure requirements, and require a non-white proxy card color for stockholders soliciting proxies (effective 2023-12-06).","evidence_excerpt":"On December 6, 2023, the Board of Directors (the “Board”) of Crinetics Pharmaceuticals, Inc. (the “Company”) adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023069747/0000950170-23-069747-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}